<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335283">
  <stage>Registered</stage>
  <submitdate>8/04/2010</submitdate>
  <approvaldate>13/04/2010</approvaldate>
  <actrnumber>ACTRN12610000296033</actrnumber>
  <trial_identification>
    <studytitle>The effects of insulin pump therapy on an individual's physical &amp; psychological well-being and cognition.</studytitle>
    <scientifictitle>A study examining the physical, psychological and cognitive effects following commencement of continuous subcutaneous insulin infusion therapy (CSII) in Type I Diabetes.</scientifictitle>
    <utrn>U1111-1114-4972</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational study examining the effect of Continuous Subcutaneous Insulin Infusion (CSII) in terms of physical, psychological and cognitive functioning of people with Type 1 diabetes.
This study will administer questionnaires on quality of life and emotional well-being before and after the insulin pump is implanted. The overall study duration is one year with follow-ups at 3 and 6 months after pump insertion.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Endpoint: Glycated haemoglobin (HbA1c). We expect improvements in HbA1c from pre-CSII commencement to three and six-month post commencement.</outcome>
      <timepoint>Baseline, three months and six months follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in physical and emotional quality of life using validated questionnaires</outcome>
      <timepoint>Baseline, three months and six months follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in cognition with more stable blood sugar levels. It will be measured using a validated questionnaire.</outcome>
      <timepoint>Baseline, three months and six months follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with Type 1 Diabetes commencing  CSII therapy
Age 18 years to 69 years
The capacity to give and accept informed consent to participate in the research</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>69</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age under 18 years or &gt;=70 years
Chronic renal disease, stage III or IV
Psychosis or psychiatric disorder
Active cancer within last 5 years
Inability to provide informed consent (i.e. has an intellectual disability, dementia)
Unable to communicate in English</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic</primarysponsorname>
    <primarysponsoraddress>Medtronic Australasia Pty Ltd
Medtronic
97 Waterloo Road
North Ryde NSW 2113
PO Box 945
North Ryde NSW 1670</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medtronic</fundingname>
      <fundingaddress>Medtronic Australasia Pty Ltd
Medtronic
97 Waterloo Road
North Ryde NSW 2113
PO Box 945
North Ryde NSW 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The project aims to examine changes in glycosylated haemoglobin (which signifies stability of diabetes), physical, psychological and cognitive functioning following commencement of CSII therapy specifically measuring these parameters at three and six-month follow-up.
The effect of CSII will be measured via routine blood tests, questionnaires examining physical health-related Quality of life (HRQoL), diabetes specific questions, psychological well-being and cognitive functioning. Patients will attend a review clinic at the Alfred specifically for CSII patients.
Patients knowledge about their diabetes will be assessed pre and post CSII commencement (at several time points) using specific questionnaires and we will also measure glycaemic control via the recognized blood test of diabetes stability (HbA1c). The questionnaires used will include assessment of patients sense of empowerment, a self-care inventory on diabetes, a diabetes-specific treatment satisfaction questionnaire, and an emotional distress questionnaire that is diabetes specific. The aim is to assess whether CSII improves these aspects of an individuals life with CSII.

Within the project, we aim to set up a group pump review clinic for all patients commencing pump therapy at this hospital.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Alfred Hospital,
2nd floor, East Block,
Commercial Road,
Prahran, Melbourne, Victoria</ethicaddress>
      <ethicapprovaldate>1/06/2009</ethicapprovaldate>
      <hrec>PROJECT 06/09</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Geraldine Lee</name>
      <address>Baker IDI,
75 Commercial Road, Prahran,
Melbourne, Victoria 3004</address>
      <phone>+61 3 8532 1637</phone>
      <fax>+61 3 8532 1100</fax>
      <email>geraldine.lee@bakeridi.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Sue Wyatt</name>
      <address>Dept of Endocrinology &amp; Diabetes,
Alfred Hospital,
Prahran, Melbourne, Victoria 3004.</address>
      <phone>+61 3 9076 3457</phone>
      <fax>+61 3 8532 1100</fax>
      <email>s.wyatt@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Geraldine Lee</name>
      <address>Baker IDI,
75 Commercial Road, Prahran,
Melbourne, Victoria 3004</address>
      <phone>+61 3 8532 1637</phone>
      <fax>+61 3 8532 1100</fax>
      <email>geraldine.lee@bakeridi.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>